Magnetite nanoparticles as a kinetically favorable source of iron to enhance GBM response to chemoradiosensitization with pharmacological ascorbate.

ABSTRACT: Ferumoxytol (FMX) is an FDA-approved magnetite (Fe₃O₄) nanoparticle used to treat iron deficiency anemia that can also be used as an MR imaging agent in patients that can't receive gadolinium. Pharmacological ascorbate (P-AscH-; IV delivery; plasma levels ≈ 20 mM) has shown promise as an adjuvant to standard of care chemo-radiotherapy in glioblastoma (GBM). Since ascorbate toxicity mediated by H₂O₂ is enhanced by Fe redox cycling, the current study determined if ascorbate catalyzed the release of ferrous iron (Fe²⁺) from FMX for enhancing GBM responses to chemo-radiotherapy. Ascorbate interacted with Fe₃O₄ in FMX to produce redox-active Fe²⁺ while simultaneously generating increased H₂O₂

SUBMITTER: Petronek MS 

PROVIDER: S-EPMC10025281 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature